About
NGM Bio is a clinical-stage biopharmaceutical company developing first-in-class biologic medicines targeting the GDF15 pathway to treat conditions such as hyperemesis gravidarum and cancer cachexia.
Explore NGM Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.